ITGB5

Across TCGA pan-cancer cohorts, ITGB5 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ITGB5 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ITGB5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ITGB5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, UCEC, and KICH are the cancer types where ITGB5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.272	0.706	.001	21	view →
UCEC	DFS	Median	All	1.000	0.617	.005	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
STAD	OS	Median	III,IV	0.022	0.635	<.001	12	view →
LUAD	OS	Median	All	0.235	0.788	.005	9	view →
LIHC	OS	Median	II,III,IV	0.255	0.768	.018	3	view →
BRCA	OS	Median	All	0.280	0.580	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ITGB5–ESCA (OS)

Open the ESCA breakdown →